Company: BIVIW
Filing Date: 2025-08-04
Form Type: S-1/A
Source: 0001520138-25-000235
Chunk: 116

Company: BIOVIE INC.
Filing Date: 2025-08-04
Form: S-1/A
Chunk 116
---
 served in his
medical profession and commercial experience in the healthcare industry and biopharma industries.

Mr. Jim Lang, Chairman of the Board of
Directors since 2023 and has served as the Company’s director since 2016. He is currently
CEO of EVERSANA, the leading commercialization services company for the life sciences industry. In five years since he founded EVERSANA,
it is now over $1B in revenue, with >7000 employees across 40 global locations. He formerly served as the CEO of Decision Resources
Group (DRG), which he transformed into a leading healthcare data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy
Research Associates (IHS CERA), a recognized leader in energy industry subscription information products, and formerly the President
of Strategic Decisions Group (SDG), a leading global strategy consultancy. Mr. Lang holds a BS summa cum laude in electrical and computer
engineering from the University of New Hampshire and an MBA with Distinction from the Tuck School of Business. Jim Lang currently also
serves as a Director at OptimizeRX (OPRX), a Nasdaq listed Company.

Jim Lang’s qualifications to serve on our Board of Directors
are primarily based on his decades of experience as a strategy consultant, broad industry expertise, and senior-level management experience
running several healthcare and information technology companies.

Dr. Amy S. Chappell has served as a director of the Company since 2025. Since 2024, she has served as CMO of Solaxa Inc., where she oversees
clinical development of novel therapies for ataxia and nerve repair. Prior to that, Dr. Chappell was a clinical trials and neurology
consultant for various companies from 2021 to 2024. From 2020 to 2021, she was CMO of Eliem Therapeuetics, assisting it through a successful
initial public offering and advancing programs in epilepsy and mood disorders. Dr. Chappell has also served over 25 years at Eli Lilly
& Co., where she played a central role in developing and gaining US Food and Drug Administration (FDA) approvals for multiple central
nervous system indications, including for Cymbalta® in fibromyalgia and musculoskeletal pain. Dr. Chappell holds a BA from Antioch
College and an MD from Indiana University School of Medicine. She also holds numerous patents, has authored over 100 peer-reviewed publications